Therapeutic prospects of sex hormone receptor signaling in hormone-responsive cancers.

Globally, hormone-responsive cancers afflict millions of people contributing to cancer-related morbidity and mortality. While hormone-responsive cancers overburden patients, their close families, and even health budgets at the local levels, knowledge of these cancers particularly their biology and possible avenues for therapy remains poorly exploited. Herewith, this review highlights the role of sex hormones (estrogens and androgens) in the pathophysiology of hormone-responsive cancers and the exploration of therapeutic targets. Major scientific databases including but not limited to Scopus, PubMed, Science Direct, Web of Science core collections, and Google Scholar were perused using a string of search terms: Hormone-responsive cancers, androgens and cancers, estrogens and cancer, androgen receptor signalling, estrogen receptor signalling, etc.
Competing Interests: Declaration of Competing Interest To the best of our knowledge, this manuscript has not been submitted either in part or whole for publication elsewhere. None of the authors has any potential financial, political, religious or personal conflict of interest related to this study. All authors have read and approved the final version of the manuscript.
(Copyright © 2024. Published by Elsevier Masson SAS.)